Clinical Trials Logo

Niemann-Pick Disease, Type C1 clinical trials

View clinical trials related to Niemann-Pick Disease, Type C1.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04860960 Active, not recruiting - Clinical trials for Niemann-Pick Disease, Type C1

Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1

TransportNPC
Start date: July 20, 2021
Phase: Phase 3
Study type: Interventional

A prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 3 and older with confirmed diagnosis of Niemann Pick disease type C1 (NPC1). The objective of this study is to evaluate the safety, tolerability and efficacy of 2000 mg/kg dose of Trappsol Cyclo (hydroxypropyl betacyclodextrin) administered intravenously compared to standard of care. An open-label sub-study in countries following European Medicines Agency (EMA) guidance will enroll asymptomatic or symptomatic patients from infancy up to age 3 to evaluate safety in that population.

NCT ID: NCT03893071 Active, not recruiting - Clinical trials for Niemann-Pick Disease, Type C1

Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C

Start date: May 23, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to provide continued access to treatment for NPC-1 after participation and completion of the Phase I trial CTD-TCNPC-101, when administered at doses of 1500 mg/kg and 2500 mg/kg by slow IV infusion over a period of 8 to 9 hours every two weeks.

NCT ID: NCT03201627 Active, not recruiting - Clinical trials for Niemann-Pick Disease, Type C1

Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease

Start date: July 5, 2017
Phase: Early Phase 1
Study type: Interventional

This study is planned to study whether lithium carbonate has protective effect on the brain of Niemann-Pick disease type C1.